期刊文献+

幽门螺杆菌感染对晚期胃癌自体DC-CIK维持治疗的影响 被引量:5

Influence of Helicobacter pylori infection on autologous DC-CIK maintenance therapy in the advanced gastric cancer patients
原文传递
导出
摘要 目的:对比幽门螺杆菌(Helicobacter pylori,Hp)感染阴性和阳性的晚期胃癌患者接受自体树突状细胞联合细胞因子诱导的杀伤(dendritic cells-cytokine induced killer,DC-CIK)细胞维持治疗的疗效差异。方法:收集2010年6月至2012年6月中国人民解放军第174医院肿瘤中心收治的72例晚期胃癌患者,年龄29~90岁,中位年龄56岁,通过胃镜检查进行胃癌确诊并检测Hp,分为Hp阳性组(45例)及Hp阴性组(27例),在接受手术或/和放化疗后,接受2疗程自体DC-CIK维持治疗,比较两组外周血培养的DC分化成熟情况及临床疗效差异。结果:两组DC成熟过程形态变化无差异;Hp阳性组DC表面分子CD83、CD86表达显著高于Hp阴性组(P<0.01),两组间HIA-DR表达无明显差异(P>0.05)。Hp阳性组治疗后生活质量评分(KPS)、外周血T细胞亚群(CD3+、CD4+、CD8+)比例较治疗前显著提高(P<0.05),肿瘤标志物(CEA、CA199、CA724)表达较治疗前下降(P<0.05)。Hp阴性组治疗后肿瘤标志物表达、外周血T淋巴细胞比例较治疗前显著降低(P<0.05),KPS评分较治疗前无明显变化(P>0.05)。Hp阳性组治疗后KPS评分、CEA和CA199表达以及CD3+和CD4+T细胞数量等的改善均优于Hp阴性组(P<0.05),但瘤体稳定率、CA724、CD8+T细胞比例无显著差异(P>0.05)。共随访2年,阳性组患者中位生存期为12.64个月,长于阴性组的11.42个月(P<0.05)。结论:携带Hp抗原信息的DC疫苗协同CIK治疗能够提高Hp感染的晚期胃癌患者的自身免疫功能,达到稳定瘤体、改善生活质量、延长生存期的目的。 Objective: To evaluate the effect of Helicobacter pylori( Hp) infection on the outcome of maintenance therapy with autologous dendritic cells-cytokine induced killer( DC-CIK) cells in gastric cancer patients. Methods: Seventytwo patients with advanced gastric cancer,aged 29-90 years,who were admitted to the Department of Oncology of No. 174 Hospital of PLA between June,2010 and June,2012 were included in this study. Based on the gastroscopic findings,patients were divided into two groups: Hp-positive and Hp-negative. Both groups received two courses of autologous DC-CIK immunotherapy after surgery or radiotherapy and chemotherapy. At the end of treatment,DC differentiation and maturation,treatment efficacy and patients outcomes in the two groups were analyzed. Results: No significant difference was observed in the morphology and maturation status of DCs between two groups( P > 0. 05). Levels of CD83 and CD86 on the surface of DCs were significantly higher in the Hp-positive group than those in the Hp-negative group( P < 0. 01),but surface levels of HLA-DR in DCs had no significant difference between two groups( P > 0. 05). In the Hp-positive group,the quality of life KPS score and levels of T lymphocyte markers( CD3+,CD4+and CD8+) were significantly increased( P < 0. 05) but levels of tumor markers CEA,CA199 and CA724 were significantly decreased( P < 0. 05) after treatment. In the Hp-negative group,levels of tumor markers and the T lymphocyte markers were significantly different before and after treatment( P < 0. 05),but the KPS score was not significantly improved( P > 0. 05). Hp-positive patients had better KPS score,higher levels of CEA and CA199,and more abundant CD3+CD4+T cells than Hp-negative patients( P< 0. 05). In contrast,the two groups did not significantly differ in tumor stability,CA724 expression,and the number of CD8+T cells( P > 0. 05). At the end of 2-years follow-up,the median survival time was 12. 64 months in the HP-positive group and 11. 42 months in the HP-negative group( P < 0. 05). Conclusion: Hp infection may help stabilize the tumor size,improve the quality of life,and prolong the survival time in patients with advanced gastric cancer undergoing maintenance therapy with DC-CIK cells.
出处 《中国肿瘤生物治疗杂志》 CAS CSCD 北大核心 2015年第1期67-72,共6页 Chinese Journal of Cancer Biotherapy
基金 南京军区医学科技创新课题资助(No.10MA068) 厦门市科技计划创新项目资助(No.3502z20134026 No.3502z20144034)~~
关键词 DC-CIK 幽门螺杆菌 胃癌 dendritic cells-cytokine induced killer(DC-CIK) cell Helicobacter pylori gastric cancer
  • 相关文献

参考文献20

  • 1蔡俊霞,谭洁,王彬,吴锦昌.DC-CIK治疗43例晚期非小细胞肺癌的近期疗效观察[J].现代肿瘤医学,2014,22(1):67-70. 被引量:30
  • 2Azoitei Ninel,Pusapati Ganesh Varma,Kleger Alexander,M?ller Peter,Küfer Rainer,Genze Felicitas,Wagner Martin,van Lint Johan,Carmeliet Peter,Adler Guido,Seufferlein Thomas.Protein kinase D2 is a crucial regulator of tumour cell-endothelial cell communication in gastrointestinal tumours. Gut . 2010
  • 3Rathbone Michael,Rathbone Barrie.Helicobacter pylori and Gastric Cancer. Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer . 2011
  • 4Giulia Mesiano,Maja Todorovic,Loretta Gammaitoni,Valeria Leuci,Lidia Giraudo Diego,Fabrizio Carnevale-Schianca,Franca Fagioli,Wanda Piacibello,Massimo Aglietta,Dario Sangiolo.Cytokine-induced killer (CIK) cells as feasible and effective adoptive immunotherapy for the treatment of solid tumors[J]. Expert Opinion on Biological Therapy . 2012 (6)
  • 5Chattopadhyay Ranajoy,Bhattacharyya Asima,Crowe Sheila E.Dual regulation by apurinic/apyrimidinic endonuclease-1 inhibits gastric epithelial cell apoptosis during Helicobacter pylori infection. Cancer Research . 2010
  • 6Chantale Bernatchez,Laszlo G. Radvanyi,Patrick Hwu.Advances in the Treatment of Metastatic Melanoma: Adoptive T-Cell Therapy[J]. Seminars in Oncology . 2012 (2)
  • 7甘露,张霞,潘军,柳珂,李萍,王喜,王杰军.幽门螺杆菌感染状态与胃癌预后的关系[J].第二军医大学学报,2011,32(12):1300-1305. 被引量:9
  • 8曹妮达,赵爱光,杨金坤.中西医结合治疗晚期胃癌生存期分析[J].中西医结合学报,2010,8(2):116-120. 被引量:38
  • 9Kranzer Katharina,Eckhardt Alexander,Aigner Michael,Knoll Gertrud,Deml Ludwig,Speth Cornelia,Lehn Norbert,Rehli Michael,Schneider-Brachert Wulf.Induction of maturation and cytokine release of human dendritic cells by Helicobacter pylori. Infection and Immunity . 2004
  • 10Chen-Si Lin,Pei-Juin He,Nu-Man Tsai,Chi-Han Li,Shang-Chih Yang,Wei-Tung Hsu,Ming-Shiang Wu,Chang-Jer Wu,Tain-Lu Cheng,Kuang-Wen Liao.A potential role for Helicobacter pylori heat shock protein 60 in gastric tumorigenesis[J]. Biochemical and Biophysical Research Communications . 2010 (2)

二级参考文献66

  • 1杨金坤,郑坚.有瘤体必虚 有虚首健脾──邱佳信治疗消化道恶性肿瘤的学术经验[J].上海中医药杂志,1995,29(2):8-10. 被引量:77
  • 2赵海磊,赵爱光,尤圣富,顾缨,唐莱娣,杨金坤.健脾中药复方胃肠安对人胃癌裸小鼠原位移植瘤生长和转移的影响[J].中西医结合学报,2005,3(5):378-381. 被引量:25
  • 3秦叔逵,龚新雷.晚期胃癌化疗的现状和新进展[J].临床肿瘤学杂志,2006,11(9):641-652. 被引量:269
  • 4崔巍,王立辉,周晓棉,宋敏.幽门螺旋杆菌感染与胃癌中Shh和C-myc表达的关系[J].微生物学杂志,2007,27(2):25-28. 被引量:5
  • 5沈自尹 王文健.中医虚证辨证参考标准[J].中西医结合杂志,1986,6(10):598-598.
  • 6Van Cutsem E. The treatment of advanced gastric cancer: new findings on the activity of the taxanes. Oncologist. 2004; 9(Suppl 2): 9-15.
  • 7中国抗癌协会.新编常见恶性肿瘤诊治规范.第2版.北京:中国协和医科大学出版社.1999.
  • 8Shimada K, Ajani JA. Adjuvant therapy for gastric carcinoma patients in the past 15 years: a review of West ern and oriental trials. Cancer. 1999, 86 (9): 1657 -1668.
  • 9Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, Miyashita K, Nishizaki T, Kohayashi O, Takiyama W, Toh Y, Nagaie T, Takagi S, Yamamura Y, Yanaoka K, Orita H, Takeuchi M. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trials): a phase III trial. Lancet Oncol. 2008; 9(3): 215-221.
  • 10Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, Middleton G, Daniel F, Oates J, Norman AR; Upper Gastrointestinal Clinical Studies Group of the National Cancer Research Institute of the United Kingdom. Capecitahine and oxaliplatin for advanced esophagogastric cancer. N EnglJ Med. 2008; 358(1): 36-46.

共引文献92

同被引文献56

引证文献5

二级引证文献85

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部